PKM and colorectal cancer: Moreover, PKM2 expression has been inversely correlated with resistance to several chemotherapeutics, including cisplatin, and oxaliplatin in gastric and colorectal cancers, respectively (48–50), The molecular mechanism underlying this is BMF, serving as a possible target gene of PKM2 that is involved in the oxaliplatin response and resistance in colorectal cancer via non-glycolysis (49).